Connect your AI

FFAI FFAI Gain (Loss) On Settlement Of Accrued Research And Development

Discontinued — last reported Q4 '25

Gain (Loss) On Settlement Of Accrued Research And Development at other companies

Assembly BiosciencesASMB

-$849K-408%

BioSig Technologies, Inc.STEX

$167K—

electroCore, Inc.ECOR

$655K0.0%

First BanCorpFBP

$0—

KEE

Keel Infrastructure Corp. Common StockKEEL

$236.25K—

RDI

Reading International, Inc.RDI

$112.5K+270%

Segments

By segment

AIEV$0—

AIXC$0—

Robotics$0—

Other financials

Income statement

Revenue$512.0K+62.0%

Gross profit-$11.4M+46.0%

Operating income-$35.9M+18.1%

Net income-$38.9M-278%

EPS (diluted)-$0.18-28.6%

Balance sheet

Cash & equivalents$12.3M+29.1%

Total debt$62.5M+46.4%

Total equity-$12.4M-109%

Total assets$250.1M-39.1%

Cash flow

Operating cash flow-$31.5M-55.1%

CapEx$221.0K-85.9%

Free cash flow-$31.7M-45.0%

Valuation

Market cap$80.37M-44.5%

Enterprise value$130.58M-29.4%

P/S109.8×-126×

Profitability

Gross margin-12,032.7%+3,469pp

Operating margin-44,142.6%-130,545pp

Net margin-57,277.9%+66,395pp

FCF margin-17,083.3%+43,535pp

Returns & leverage

Return on equity-320.2%-2,578pp

Debt / equity0.9×+0.8×

Current ratio0.4×0.0×

Where this comes from

Reported directly by FFAI in its filing.

Tagged under the XBRL concept ffie:GainLossOnSettlementOfAccruedResearchAndDevelopment.

The official record: FFAI’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about FFAI's gain (loss) on settlement of accrued research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is FFAI's gain (loss) on settlement of accrued research and development?: FFAI (FFAI) reported gain (loss) on settlement of accrued research and development of $0 in Q4 2025.
What does gain (loss) on settlement of accrued research and development mean?: This metric represents the financial impact resulting from the final settlement or adjustment of previously accrued research and development liabilities. It reflects changes in estimated costs for R&D projects that are resolved during the reporting period. Investors use this to assess the accuracy of prior R&D accruals and the impact of one-time adjustments on operating expenses.